I describe the effect of new vitamin D analogues, that is 1alpha,24R (OH)(2)D(3), 22-oxacalcitriol, 1alpha,25 (OH)(2)D(3) injection which have been used clinically, 24R,25 (OH)(2)D(3) which was stopped in development, and 26,27-F(6)-1alpha,25 (OH)(2)D(3), and ED-71, 1alpha,25 (OH)(2)-16-ene-23-yne-D(3), and 1alpha,25 (OH)(2)-16-ene-23-yne-26,27-F(6)-D(3) which are under development, on phosphate metabolism. Examinations of these new vitamin D analogues on phosphate metabolism are insufficient, and we have to wait for the result of research in this field.